

1 Value of 3D-echocardiography to improve prediction of mitral valve

2 reoperation in patients with congenital mitral valve disease

3
4
5 Nora Lang^{a,d}, Steven J. Staffa^b, David Zurakowski^b, Francesca Sperotto^a, Melinda Shea^a,
6 Christopher W. Baird^c, Sitaram Emani^c, Pedro J. del Nido^c, Gerald R. Marx^a

7
8 Department of Cardiology^a, Department of Surgery^b, Department of Anesthesiology, Critical
9 Care and Pain Medicine^b, and Department of Cardiovascular Surgery^c, Boston Children's
10 Hospital, Harvard Medical School, Boston, Massachusetts, USA
11 Department of Pediatric Cardiology^d, University Heart & Vascular Center Hamburg, University
12 Medical Center Hamburg-Eppendorf, Hamburg, Germany

13
14
15 **Short title:** Prediction of mitral valve reoperation by 3DE

16 **Total word count (including title page, abstract, references, tables, and figure legends):**

17 7095 words

24 **Corresponding authors:**

25 Gerald R. Marx, MD

26 Department of Cardiology

27 Boston Children's Hospital

28 300 Longwood Avenue

29 Boston, MA 02115

30 Email: Gerald.marx@cardio.chboston.org

31
32 Nora Lang, MD, PhD

33 Department of Pediatric Cardiology

34 University Heart & Vascular Center Hamburg

35 University Medical Center Hamburg-Eppendorf

36 Hamburg, Germany

37 Email: n.lang@uke.de

38

39

40 **ABSTRACT (350 words)**

41

42 **BACKGROUND**

43 Congenital mitral valve disease (CMVD) presents major challenges in medical and surgical
44 management. Data on predictors of mitral valve (MV) reoperation and value of 3D-
45 echocardiography (3DE) in this context are currently limited. Aim of our study was to identify
46 predictors of MV reoperation and to investigate the value of 3DE in risk stratification.

47

48 **METHODS**

49 All children <18 years old who underwent MV reconstruction for CMVD from 2002 to 2018
50 were included. Pre- and postoperative 2D-echocardiogram (2DE) and 3DE data were collected.
51 Competing risks and Cox regression analyses were used to identify independent predictors of
52 MV reoperation. Receiver operating characteristics curve (ROC) analysis was used to assess the
53 predictive values of 3DE versus 2DE. Decision tree analysis was used to compute decision
54 algorithms.

55

56 **RESULTS**

57 Over the course of the study period, 206 children underwent MV reconstruction for CMVD: 105
58 had mitral stenosis (MS), 75 had mitral regurgitation (MR), and 26 had mixed disease (MD). Of
59 them, 64 (31%) required a MV-reoperation. At multivariable analysis, age <1 year (hazard ratio
60 [HR]=2.65; 95% confidence interval [CI]:1.13-6.21), tethered leaflets (HR=2.00; 95% CI:1.05-
61 3.82;), moderate or greater 2DE postoperative MR (HR=4.26; 95% CI:2.45-7.4), as well as
62 changes in 3D-effective orifice area (3D-EOA) and in 3D-vena contracta regurgitant area (3D-
63 VCRA) were all found to be independent predictors of MV reoperation. By ROC analysis,

64 changes in 3D-EOA and 3D-VCRA were found to have significantly higher predictive value than
65 changes in mean gradients (AUC=0.847 vs AUC=0.676, $P=0.006$) and 2D-VCRA (AUC=0.969
66 vs AUC=0.720, $P=0.012$), respectively. Decision-tree analysis found that a <30% increase in 3D-
67 EOA had 80% accuracy (HR=8.50; 95% CI:2.9-25.1) and a <40% decrease in 3D-VCRA had
68 93% accuracy (HR=22.50; 95% CI:2.9-175) in predicting MV reoperation for stenotic and
69 regurgitant MV, respectively.

70

71 **CONCLUSIONS**

72 Age <1 year, tethered leaflets, 2DE postoperative MR, changes in 3D-EOA and 3D-VCRA were
73 all independent predictors of MV-reoperation. 3DE parameters had higher predictive value than
74 2DE. 3DE-based decision-tree algorithms may help risk stratification and serve as a support tool
75 for clinical decision-making in patients with CMVD.

76

77

78 **KEYWORDS**

79 3D-echocardiography, congenital mitral valve disease, mitral stenosis, mitral regurgitation,
80 prediction, outcomes

81

82

83 **CLINICAL PERSPECTIVES**

84 **What is new?**

- 85 • In congenital mitral valve (MV) disease patients undergoing MV reconstruction, changes
86 in 3D effective orifice area (3D-EOA) and 3D vena contracta regurgitant area (3D-
87 VCRA) were found to be independent predictors of MV reoperation.
- 88 • Changes in 3D effective orifice area (3D-EOA) and 3D vena contracta regurgitant area
89 (3D-VCRA) had significantly higher predictive value compared to 2D-echocardiography
90 parameters, i.e. changes in mean gradient, 2D-VCRA and moderate or greater
91 postoperative 2D mitral regurgitation.
- 92 • Decision tree analysis identified cut-off points in changes of 3D-EOA and 3D-VCRA to
93 predict MV reoperation.

94

95 **What are the clinical implications?**

- 96 • Changes in 3D-EOA and 3D-VCRA can be measured in the operating room to consider
97 return to bypass, or at discharge, to help inform need for early follow-up and MV
98 reoperation.
- 99 • 3DE-based decision tree predictive algorithms may help in risk stratification and serve as
100 a support tool to facilitate clinical decision-making.

101

102

103 **NON-STANDARD ABBREVIATIONS AND ACRONYMS**

104 2DE: 2-dimensional echocardiography

105 3DE: 3-dimensional echocardiography

106 AUC: area under the curve

107 CI: confidence interval

108 EOA: effective orifice area

109 HLHS: hypoplastic left heart syndrome

110 HR: hazard ratio

111 IQR: interquartile range

112 LVEDP: left ventricular end diastolic pressure

113 MD: mixed disease

114 MR: mitral regurgitation

115 MS: mitral stenosis

116 MV: mitral valve

117 N: number

118 ROC: receiver operating characteristic

119 VCRA: vena contracta regurgitant area

120 **INTRODUCTION**

121 Congenital mitral valve disease (CMVD) is a rare and heterogenous congenital heart disease
122 (CHD) with variable anatomic characteristics and prognosis. The disease may affect multiple
123 segments of the valve apparatus including the supralvalvar region, annulus, leaflets, commissures,
124 as well as the subvalvar region¹⁻². Despite medical management, children with CMVD often
125 require catheter-based or surgical interventions³. MV repair is generally preferred over MV
126 replacement due to its ability to preserve the subvalvar apparatus and its function, conserve the
127 overall ventricular geometry, and allow tissue growth over time⁴⁻⁷. However, studies have shown
128 that surgical results have been burdened by a non-negligible proportion of reoperation for either
129 MV reconstruction or replacement^{3,5,8}.

130
131 The identification of factors possibly associated with higher risk of reoperation may help guide
132 risk stratification and management in this peculiar cohort of patients. In the last decades, studies
133 have tried to identify predictors of MV reoperation in patients with CMVD^{5,8-10}. However, often
134 these studies were affected by small sample sizes, or included patients with marked heterogeneity
135 in their baseline MV pathology^{7,9}. Few studies have addressed the value of echocardiography
136 techniques to predict MV reinterventions⁹⁻¹⁰.

137
138 Traditionally, cardiologists and cardiac surgeons have relied on 2D-echocardiography (2DE) for
139 monitoring and guiding the clinical management in these patients. 3D-echocardiography (3DE)
140 provides the simultaneous assessment of the spatial relationship of the leaflets, chordae and
141 papillary muscles, and thus more accurate and reliable measurements¹¹⁻¹³, which have the
142 potential to aid surgical planning¹⁴. To date, most reports assessing the benefit of 3DE in cardiac
143 diseases have been conducted in adult patients^{11,15-16}. The use of 3DE in children with CHD has

144 been reported only for specific settings, like the evaluation of atrioventricular (AV) septal defects
145 *status post* repair¹⁷⁻¹⁸ or the assessment of the tricuspid valve in children with hypoplastic left
146 heart syndrome (HLHS)¹⁸⁻²⁰.

147
148 The main purpose of this study was to investigate independent predictors of MV reoperation in a
149 large cohort of pediatric patients with CMVD. In addition to traditional patient demographics,
150 anatomic and clinical characteristics, we sought to assess 3DE measurements as predictors of MV
151 reoperation, and to investigate the relative performance of the 3DE compared to the 2DE in this
152 setting. Finally, we aimed to develop decision-tree algorithms for patients' risk stratification to
153 serve as a support tool for clinicians in the clinical decision-making.

154

155 MATERIAL AND METHODS

156 *Patients*

157 The Cardiovascular Surgical Department database at Boston Children's Hospital (Boston, MA)
158 was searched for all patients <18 years who underwent MV surgery between January 2002 and
159 December 2018. The Institutional Review Board at Boston Children's Hospital approved the
160 study with a waiver for informed consent (IRB-P00023266).

161 Patients with HLHS who underwent single ventricle palliation, patients with AV-canal defects,
162 AV-discordance, and those with connective tissue disorders were excluded. Patients were
163 subdivided into three subgroups according to the type of MV disease as follows: (1) mitral
164 stenosis (MS) group: patients with a Doppler mean gradient >5 mmHg and none or trivial MR;
165 (2) mitral regurgitation (MR) group: patients with a mean gradient <5 mmHg and at least
166 moderate MR; (3) mixed disease (MD) group: patients with a mean gradient >5 mmHg and at
167 least moderate MR. Anatomical characteristics of the MV were determined based on the
168 description of the MV in the surgical report, as detailed in the **Supplemental Methods**.

169

170 *Outcomes*

171 The primary outcome measure was MV reoperation. Secondary outcome measures were need for
172 MV replacement and death at any time to last follow-up.

173

174 *Echocardiographic measurements*

175 Echocardiographic measurements were performed preoperatively (within 7 days before surgery)
176 and postoperatively either at hospital discharge or at 10 days after surgery, whichever came first.

177

178

179 2DE measurements

180 Qualitative grading of the MR was obtained from the echocardiographic report and was classified
181 as trivial, mild, moderate, or severe. Doppler mean gradients and mitral 2D-VCRA were
182 calculated by 2 independent investigators. The severity of MS was graded as follows: trivial: <3
183 mmHg; mild: 3–5 mmHg; moderate: >5 to 10 mmHg, and severe: >10 mmHg. 2D-VCRA was
184 measured from two orthogonal diameters, and the area was calculated from the equation of an
185 ellipse ($\pi*(d/2)^2$).

186
187 3DE measurements

188 Electrocardiographic-gated full-volume 3DE acquisitions were performed using a 5–1 MHz
189 matrix-array transthoracic probe and a 3DE ultrasound system (SONOS 7500 and iE33, Philips
190 Medical Systems, Bothwell, WA). Full-volume 3DE data were acquired from the apical four-
191 chamber view. Analyses were performed with a dedicated software (Q-lab 6.0, Philips Medical
192 Systems, Bothwell, WA). Multi-planar reconstruction was used to locate the cross-sectional plane
193 to measure the annulus area, 3D-EOA and 3D-VCRA (**Figure 1A and B**). Based on two
194 orthogonal long-axis planes, a corresponding short-axis plane was chosen to appropriately trace
195 the MV annulus area, 3D-EOA, and 3D-VCRA (**Figure 1A and 1B**), which were blindly
196 measured by 2 independent investigators. Each investigator repeated these measurements blindly
197 after 2 weeks.

198
199 ***Statistical Analysis***

200 Demographic and anatomic characteristics are summarized using frequencies and percentages for
201 categorical data, medians and interquartile ranges (IQR) for continuous data. Paired t-test was
202 used to assess variation of echocardiographic parameters over time (pre- and postoperatively).

203 The Kaplan Meier estimator was used to compute freedom from MV reoperation, MV
204 replacement, and death at 1, 3, and 5 years after the first MV operation and 95% confidence
205 intervals (CIs). Inter- and intra-rater agreement of 3DE measurements were tested using intra-
206 class correlation coefficients (ICC) based on a two-way mixed effects modeling, with reliability
207 categories defined as follows: ICC <0.50 poor, 0.50-0.75 moderate, 0.75-0.90 good, >0.90
208 excellent.

209 Univariate and multivariable competing risk regression analyses using Fine-Gray modeling were
210 used to identify significant demographic, clinical, and 2DE predictors of MV reoperation,
211 accounting for mortality prior to reoperation as a competing risk event²¹⁻²². Preoperative factors
212 included in the model were age, weight, sex, type of disease (MS, MR, MD), pulmonary
213 hypertension, thickened and tethered leaflets, presence of endocardial fibroelastosis (EFE), year
214 of surgery; postoperative factors were presence of moderate or greater MR and presence of
215 moderate or greater MS postoperatively. All factors were included in the multivariable model.
216 Cumulative incidence functions were constructed overall and for diagnostic subgroups for
217 independent predictors using Nelson-Aalen estimators. To better investigate any independent
218 2DE predictor resulted from this model, the same model was reproduced for the subgroups of
219 patients with MS (including MD) and MR (including MD). 3DE measurements were tested as
220 predictors of MV-reoperation using univariate and multivariable time-to-event Cox proportional
221 hazards regression analysis, for the MS (including MD) and the MR (including MD) populations
222 separately. Factors found to be significant at univariate analysis were included in the
223 multivariable model. The proportional sub-distribution hazard assumption was tested using
224 Schoenfeld residuals²³ and the Grambsch-Therneau test. Results are presented as adjusted hazard
225 ratios (HR) and 95% CIs.

226 The prognostic value of 2DE versus 3DE measurements in predicting MV-reoperation was
227 assessed by the area under the curve (AUC) of the receiver operating characteristic curves, which
228 were compared using the paired-DeLong test²⁴. Classification and regression tree analysis was
229 implemented to determine the optimal cut-points for 3DE measurements in predicting MV-
230 reoperation (*rpart* package, R). Results from decision-tree analysis are presented with sensitivity,
231 specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of the
232 optimized predictive cutoff thresholds. Bootstrap validation was used to evaluate the internal
233 validity and model performance²⁵ (**Supplemental Methods**). Statistical analyses were performed
234 using Stata (version 16.0, StataCorp LLC, College Station, Texas) and R (version 3.4.3, R
235 Foundation for Statistical Computing, Vienna, Austria). A two-tailed alpha level of 0.05 was
236 considered statistically significant.

237

238

239 RESULTS

240 *Demographic and anatomic MV characteristics*

241 Two-hundred-and-six patients (48% female) underwent MV surgery during the study period.
242 One-hundred-and-five patients (51%) had MS, 75 (36%) MR, and 26 (13%) MD. Eight percent
243 were neonates, 47% were infants. The median age at the initial MV operation was 17 months
244 (IQR: 5-56), the median weight was 9.1 kg (IQR: 5-16.7). Surgical anatomic MV characteristics
245 are shown in **Table 1**. At time of the initial operation, MD patients were younger (median age 5
246 months, IQR: 1-21) and smaller in weight (median weight 5.1 kg, IQR: 3.3–11.4). MR patients
247 were older (median age 48 months, IQR: 5–73) and weighed more (median weight 13.7 kg, IQR:
248 5.2-19.6). Median follow-up for the total cohort was 60 months (IQR: 18-108) (**Table 1**).

249

250 *Mortality*

251 At a median follow-up of 60 months (IQR: 18-108), 13 (6%) patients did not survive. Death
252 occurred at a median of 15 months (IQR: 2-42) after the first MV operation. The highest
253 mortality rate was observed in MD patients (4/26, 15%), while the lowest was reported in MR
254 patients (2/75, 3%). There was one peri-operative/early death (<30 days) in 2005. The overall
255 survival was 97.2% at 1 year (95% CI: 93.3%-98.8%; n=164), 94.7% at 3 years (95% CI: 90%-
256 97.2%; n=131) and 93.9% at 5 years (95% CI: 88.9%-96.7%; n=98).

257

258 *MV Reoperation and replacement*

259 Sixty-four patients (31%) required MV reoperation at a median time of 9 months after the first
260 operation (IQR: 0.4-39). Thirty-three (16%) patients required more than one MV reoperation.
261 Twenty-six (12.6%) required a MV replacement, at a median time of 46 months since the first
262 operation (IQR: 0.9-18). Overall freedom from MV reoperation was 79.1% at 1 year (95% CI:

263 72.4%-84.4%; n=132), 73.9% at 3 years (95% CI: 66.6%-79.8%; n=97) and 66% at 5 years (95%
264 CI: 57.7%-73%; n=64). Thirty-six patients who underwent reoperation had MS (34% of MS), 16
265 MR (21% of MR), and 12 MD (46% of MD). Overall freedom from MV-replacement was 89.9%
266 at 1 year (95% CI: 84.4%-93.5%; n= 150), 87.9% at 3 years (95% CI: 82%-91.9%; n=114) and
267 85.4% at 5 years (95% CI: 78.9%-90%; n=82). Seventeen patients who underwent MV-
268 replacement had MS (16% of MS), 4 MR (5% of MR), and 5 MD (19% of MD).

269

270 *Demographic, anatomic and 2DE predictors for MV-reoperation*

271 At univariate competing risks regression analysis, age <1 year, MD, tethered leaflets, and
272 moderate or greater postoperative MR or MS were found to be associated with MV reoperation
273 (**Table 2**). Multivariable modeling (**Table 2**) confirmed that age <1 year (adjusted HR=2.65;
274 95% CI: 1.13-6.21), tethered leaflets (adjusted HR=2.00; 95% CI: 1.05-3.82) and a qualitatively
275 moderate or greater postoperative MR (adjusted HR=4.26; 95% CI: 2.45-7.40; **Figure 2A**) were
276 independent predictors of MV reoperation. When stratifying for type of MV disease, moderate or
277 greater postoperative MR was confirmed to be an independent predictor for both patients with
278 stenotic MV (**Figure 2B**; adjusted HR=3.21; 95% CI: 1.73-6.00) and patients with regurgitant
279 MV (**Figure 2C**; adjusted HR=7.38; 95% CI: 3.46-15.70).

280

281 *Inter- and intra-rater agreement of 3DE measurements*

282 The inter-rater agreement was good for 3D-EOA (ICC=0.75), and excellent for both the 3D-
283 VCRA and annulus area (ICC=0.93 and ICC=0.98, respectively). Intra-rater reliability was
284 excellent for all parameters (EAO: ICC=0.92; 3D-VCRA: ICC=0.97; annulus area: ICC=0.99).

285

286

287 ***3DE predictors for MV reoperation***

288 **Supplementary Video 1 and 2** show examples of 3DE in two patients with congenital MS and
289 MR, respectively. Eighty-six out of 206 patients (42%) had pre- and postoperative 3DE data
290 available. For stenotic valves, the 3D-EOA significantly increased after MV-reoperation, from
291 $0.91 \pm 0.55 \text{ cm}^2/\text{m}^2$ to $1.44 \pm 0.69 \text{ cm}^2/\text{m}^2$ ($P < 0.001$). 3D-VCRA trended to increase from
292 $0.93 \pm 1.50 \text{ cm}^2/\text{m}^2$ to $1.49 \pm 2.07 \text{ cm}^2/\text{m}^2$, although not significantly ($P = 0.143$). On univariate
293 analysis, preoperative 3D-EOA, early changes in 3D-EOA and 3D-VCRA, and size of the
294 postoperative 3D-VCRA were positively associated with MV reoperation. On multivariable
295 analysis, early changes in 3D-EOA and 3D-VCRA were confirmed to be independently
296 predictive of MV reoperation (**Table 3**; 3D-EOA: adjusted HR=0.26; 95% CI: 0.07-0.99; and
297 3D-VCRA: adjusted HR=2.86; 95% CI: 1.09-7.48). For regurgitant valves, the 3D-VCRA
298 significantly decreased from $2.22 \pm 2.26 \text{ cm}^2/\text{m}^2$ to $1.46 \pm 1.94 \text{ cm}^2/\text{m}^2$ ($P = 0.017$), 3D-EOA
299 significantly decreased from $2.91 \pm 1.86 \text{ cm}^2/\text{m}^2$ to $1.63 \pm 0.73 \text{ cm}^2/\text{m}^2$ ($P = 0.005$), and the annuli
300 significantly decreased from $7.53 \pm 3.45 \text{ cm}^2/\text{m}^2$ to $4.53 \pm 1.85 \text{ cm}^2/\text{m}^2$ ($P < 0.001$). Univariate
301 analysis showed that the size of the preoperative 3D-VCRA, size of the postoperative 3D-VCRA,
302 early changes in 3D-VCRA, and preoperative annulus were positively associated with MV
303 reoperation. On multivariable analysis, early changes in 3D-VCRA were confirmed to be an
304 independent predictor of MV reoperation (**Table 3**; adjusted-HR=11.77; 95% CI: 3.06-45.3).

305

306 ***Comparison of 2DE vs 3DE measurements predictive values***

307 **Figure 2** and **Table 4** showed the comparison of predictive values of 3DE vs 2DE parameters.
308 When considering stenotic valves, early changes in 3D-EOA was found to be a stronger predictor
309 of MV reoperation than 2DE early changes in mean gradients (AUC 0.847 [95% CI: 0.723-
310 0.970] vs 0.676 [95% CI: 0.508-0.844], respectively; DeLong test $P = 0.006$, **Figure 3A**). For

311 regurgitant valves, early changes in 3D-VCRA was found to be a stronger predictor of MV-
312 reoperation than 2DE qualitative postoperative MR (AUC=0.969 [95% CI: 0.916-0.999] vs 0.751
313 [95% CI: 0.642-0.860], respectively; DeLong test $P<0.001$). Additionally, early changes in 3D-
314 VCRA was a significantly stronger predictor of MV-reoperation than early changes in 2D-VCRA
315 (AUC=0.969 [95% CI: 0.916-0.999] vs 0.720 [95% CI: 0.424-0.903], DeLong test $P=0.012$;
316 **Figure 2B**).

317
318 *Decision-tree predictive algorithms for risk stratification*
319 Decision-tree predictive algorithms were computed as a support tool for clinical decision-making
320 (**Figure 4**). Sensitivity, specificity, positive and negative predictive values are reported in **Table**
321 **4**. For stenotic valves, an increase in 3D-EOA by <30% leads to 92% risk of MV-reoperation
322 (accuracy 80%; HR=8.50; 95% CI: 2.90-25.1; $P<0.001$). For regurgitant valves, a decrease in
323 3D-VCRA <40% is associated with 93% risk of MV reoperation (accuracy 93%; HR=22.50; 95%
324 CI: 2.90-175.00; $P=0.003$). Bootstrap validation demonstrated excellent internal validity and
325 model performance (**Supplemental Results**).

326

327 **DISCUSSION**

328 This single-center study, which involved a large cohort of young pediatric patients undergoing
329 MV surgery for CMVD, showed a low mortality at a median follow-up of 5 years. However,
330 31% of patients required a MV reoperation, and 12% requiring a subsequent MV replacement.
331 These important surgical findings prompted analysis of risk factors for MV reoperation. We
332 showed that age <1 year, presence of tethered leaflets, evidence of moderate or greater
333 postoperative MR on 2DE, as well as early changes in 3D-EOA and 3D-VCRA were all
334 independent predictors of MV reoperation. Importantly, when 2DE and 3DE were compared in
335 terms of their performance to predict MV reoperation, certain 3DE parameters were found to
336 have significantly higher prognostic values compared to 2DE. Based on these findings, decision-
337 tree predictive algorithms were developed to inform patients risk stratification, with the aim to
338 improve assessment and help clinical decision-making.

339
340 The fact that younger patients, in particular patients <1 year of age, are at increased risk for MV-
341 reoperation was previously reported for smaller cohorts^{5,7-8,10,26}, and further confirmed in our
342 study. Additionally, in terms of baseline MV morphology, our study showed that patients with
343 tethered and restricted leaflets are at increased risk of MV reoperation. This is a new finding
344 compared to what was previously reported in literature. From an echocardiographic point of
345 view, we found that both 2DE and 3DE parameters were associated with MV reoperation. In
346 particular, evidence of moderate or greater postoperative MR on 2DE, as well as early changes in
347 the 3D-EOA and 3D-VCRA, were all found to be independently associated with the need for MV
348 reoperation.

349

350 Postoperative systemic AV-valve regurgitation has been shown to be associated with adverse
351 outcomes in a variety of CHDs²⁷⁻³⁰. In 43 adults with CHD undergoing primary or re-operative
352 systemic AV-valve surgery, pre-discharge systemic AV-valve regurgitation grade was the only
353 factor associated with adverse outcomes including reoperation²⁷. Similarly, studies have shown
354 that postoperative systemic AV-valve regurgitation in repaired AV-canal is associated with
355 higher risk of AV-valve reoperation²⁸⁻³⁰. Given the proven importance of this factor in
356 determining outcomes, studies have also focused on improving 2DE regurgitation assessment
357 with the evaluation of other parameters, such as 2D-VCRA. However, Prakash et al. did not find
358 that 2D-VCRA measurements in patients with AV septal defects was superior to the qualitative
359 regurgitation assessment³¹, and Yosefy et al. showed that 2D-VCRA can cause clinical
360 misclassification in 45% of adult patients with eccentric MR, while 3D-VCRA was more
361 accurate³². In fact, non-negligible changes in the AV-valve geometry have been demonstrated in
362 similar populations with CHD after AV-valve surgery, as in children with AV-canal undergoing
363 AV-valve repair³³. To date, measurements of 2D-VCRA are performed by measuring the vena
364 contracta width mostly in one plane, and in some studies in two orthogonal planes. However,
365 these types of measurement do not account for the marked irregularity of shape of the VCRA.

366
367 Several publications in adults have highlighted the advantages of 3DE for the quantitative
368 assessment of the valve function³⁴⁻³⁸, with increasing number of reports demonstrating higher
369 accuracy of 3DE compared to 2DE, and higher ability to predict outcome³⁹⁻⁴⁰. In parallel, a new
370 consensus document recently advised on the use of 3DE for surgical planning in patients with
371 CHD⁴¹. In the setting of AV-valve regurgitation, 3DE directly traces the orifice area without
372 making assumptions on the shape of the vena contracta. Simultaneous orthogonal visualization of
373 different planes allows a more precise depiction of the best cross-sectional cutting plane to trace

374 the vena contracta circumference. In adults, a strong correlation has been proven between the 3D-
375 VCRA and the regurgitation area calculated by MRI⁴². Adubiab et al. showed that measurements
376 of 3D-VCRA were superior to 2DE determination of regurgitation severity⁴⁰. However,
377 experience with quantitative 3DE in children with CHD is still limited, with only a few studies
378 assessing its potential value. Here, we showed that early changes in 3D-VCRA had significantly
379 higher predictive accuracy than both the 2DE qualitative postoperative MR assessment and the
380 early changes of 2D-VCRA.

381
382 AV-valve stenosis is also known to be associated with adverse outcomes in patients after repair
383 of CMVD or AV-canal^{10,29,43}. MV stenosis is generally assessed by 2DE using mean AV-valve
384 inflow gradients; however, this measurement presents several challenges. First, many patients
385 with CHD may have left ventricular systolic or diastolic dysfunction and therefore elevated left
386 ventricular end diastolic pressure (LVEDP), with consequent possible underestimation of the
387 stenosis, if measured using the gradient alone. Additionally, patients may have limited flow
388 across the valve due to the presence of an atrial shunt or low cardiac output. Since gradients are
389 flow dependent, this may also underestimate the magnitude of the stenosis if assessed by mean
390 inflow gradient only. Our study investigated the utility of 3DE assessment in stenotic valves, and
391 found that early changes in 3D-EOA were accurate in predicting MV reoperation. Most
392 importantly, early changes in 3D-EOA had significantly higher prognostic value than early
393 changes in 2D mean gradient.

394
395 To improve risk stratification and facilitate potential application of these findings into clinical
396 practice, decision-tree predictive algorithms were developed and subsequently bootstrapped
397 validated. Potentially, these 3DE parameters could be utilized either pre-operatively or in the

398 operating room. Early changes in 3D-EOA and 3D-VCRA measured in the operating room may
399 inform decision to return to bypass, or, if these changes are measured at discharge, they may
400 inform earlier follow-up or early MV reoperation.

401

402 *Study limitations*

403 Since this is a retrospective study, loss of information occurred and not all patients had 3DE data
404 available. As this observational study was conducted in a clinical setting with a variety of
405 providers, the criteria for MV reoperation were not defined and surgical details were not
406 investigated. The 3DE parameters identified as independent predictors were calculated using
407 postoperative changes assessed at discharge. We realize the clinical importance of identifying
408 pre-operative predictors or using the bypass echocardiogram to help guide patient management;
409 however, in the future, these measurements may be potentially used in the operating room.
410 Additionally, this study was limited by constraints of imaging, particular image resolution and
411 low frame rate. Despite these limitations, we believe this study provides a valuable framework
412 for future research investigations in the field of 3DE and in the assessment of CMVD.

413

414 *Conclusions*

415 In a large cohort of patients with CMVD, 31% of patients required MV-reoperation at a median
416 follow-up time of 5 years. Age <1 year, presence of tethered leaflets, evidence of moderate or
417 greater postoperative MR on 2DE, as well as early changes in the 3D-EOA and 3D-VCRA were
418 independent predictors of MV-reoperation. 3DE parameters were found to have significantly
419 higher predictive value compared to 2DE parameters, suggesting added value of the 3DE
420 assessment. Decision-tree predictive algorithms were developed based on these findings to

421 classify patients in terms of risk stratification and to serve as a support tool for assessment and
422 clinical decision making.

423

424

425 **Acknowledgements:** The authors thank Drs. Alejandra Bueno, Erin Krizman and Patrick Myers
426 for support with data collection. The authors also thank Dr. Jane Newburger for valuable
427 comments on the manuscript.

428
429 **Sources of Funding:** Nora Lang received the Kaplan Meier Fellowship and a fellowship from
430 the German Research Foundation.

431
432 **Disclosures:** There are no disclosures.

433

434

435 **REFERENCES**

- 436 1. Baird CW, Marx GR, Borisuk M, Emani S, del Nido PJ. Review of Congenital Mitral
437 Valve Stenosis: Analysis, Repair Techniques and Outcomes. *Cardiovasc Eng Technol*.
438 2015;6:167-173. doi: 10.1007/s13239-015-0223-0
439 10.1007/s13239-015-0223-0 [pii]
- 440 2. Seguela PE, Houyel L, Acar P. Congenital malformations of the mitral valve. *Arch*
441 *Cardiovasc Dis*. 2011;104:465-479. doi: S1875-2136(11)00247-6 [pii]
442 10.1016/j.acvd.2011.06.004
- 443 3. Delmo Walter EM, Hetzer R. Repair for Congenital Mitral Valve Stenosis. *Semin Thorac*
444 *Cardiovasc Surg Pediatr Card Surg Annu*. 2018;21:46-57. doi: S1092-9126(17)30002-9 [pii]
445 10.1053/j.pcsu.2017.11.008
- 446 4. van Rijk-Zwicker GL, Delemarre BJ, Huysmans HA. Mitral valve anatomy and
447 morphology: relevance to mitral valve replacement and valve reconstruction. *J Card Surg*.
448 1994;9:255-261.
- 449 5. Kalfa D, Vergnat M, Ly M, Stos B, Lambert V, Baruteau A, Belli E. A standardized
450 repair-oriented strategy for mitral insufficiency in infants and children: midterm functional
451 outcomes and predictors of adverse events. *J Thorac Cardiovasc Surg*. 2014;148:1459-1466. doi:
452 S0022-5223(14)00264-5 [pii]
453 10.1016/j.jtcvs.2014.02.057
- 454 6. Delmo Walter EM, Komoda T, Siniawski H, Hetzer R. Surgical reconstruction techniques
455 for mitral valve insufficiency from lesions with restricted leaflet motion in infants and children. *J*
456 *Thorac Cardiovasc Surg*. 2012;143:S48-53. doi: S0022-5223(11)01152-4 [pii]
457 10.1016/j.jtcvs.2011.10.033

- 458 7. Oppido G, Davies B, McMullan DM, Cochrane AD, Cheung MM, d'Udekem Y, Brizard
459 CP. Surgical treatment of congenital mitral valve disease: midterm results of a repair-oriented
460 policy. *J Thorac Cardiovasc Surg*. 2008;135:1313-1320; discussion 1320-1311. doi: S0022-
461 5223(07)01997-6 [pii]
462 10.1016/j.jtcvs.2007.09.071
- 463 8. Delmo Walter EM, Komoda T, Siniawski H, Miera O, Van Praagh R, Hetzer R. Long-
464 term surgical outcome of mitral valve repair in infants and children with Shone's anomaly. *Eur J*
465 *Cardiothorac Surg*. 2013;43:473-481; discussion 481-472. doi: ezs325 [pii]
466 10.1093/ejcts/ezs325
- 467 9. Selamet Tierney ES, Graham DA, McElhinney DB, Trevey S, Freed MD, Colan SD,
468 Geva T. Echocardiographic predictors of mitral stenosis-related death or intervention in infants.
469 *Am Heart J*. 2008;156:384-390. doi: S0002-8703(08)00229-9 [pii]
470 10.1016/j.ahj.2008.03.019
- 471 10. Sugimoto K, Konstantinov IE, d'Udekem Y, Brink J, Zannino D, Brizard CP. Mid-term
472 outcomes of congenital mitral valve surgery: Shone's syndrome is a risk factor for death and
473 reintervention. *Interact Cardiovasc Thorac Surg*. 2017;25:734-739. doi: 4077061 [pii]
474 10.1093/icvts/ivx211
- 475 11. Ashikhmina E, Shook D, Cobey F, Bollen B, Fox J, Liu X, Worthington A, Song P,
476 Shernan S. Three-dimensional versus two-dimensional echocardiographic assessment of
477 functional mitral regurgitation proximal isovelocity surface area. *Anesth Analg*. 2015;120:534-
478 542. doi: 10.1213/ANE.0000000000000409
479 00000539-201503000-00011 [pii]
- 480 12. Bhave NM, Lang RM. Quantitative echocardiographic assessment of native mitral
481 regurgitation: two- and three-dimensional techniques. *J Heart Valve Dis*. 2011;20:483-492.

- 482 13. Cantinotti M, Giordano R, Koestenberger M, Voges I, Santoro G, Franchi E, Assanta N,
483 Valverde I, Simpson J, Kutty S. Echocardiographic examination of mitral valve abnormalities in
484 the paediatric population: current practices. *Cardiol Young*. 2020;30:1-11. doi:
485 S1047951119003196 [pii]
486 10.1017/S1047951119003196
- 487 14. Colen T, Smallhorn JF. Three-dimensional echocardiography for the assessment of
488 atrioventricular valves in congenital heart disease: past, present and future. *Semin Thorac*
489 *Cardiovasc Surg Pediatr Card Surg Annu*. 2015;18:62-71. doi: S1092-9126(15)00006-X [pii]
490 10.1053/j.pcsu.2015.01.003
- 491 15. Bhatt HV, Spivack J, Patel PR, El-Eshmawi A, Amir Y, Adams DH, Fischer GW.
492 Correlation of 2-Dimensional and 3-Dimensional Echocardiographic Analysis to Surgical
493 Measurements of the Tricuspid Valve Annular Diameter. *J Cardiothorac Vasc Anesth*.
494 2019;33:137-145. doi: S1053-0770(18)30381-1 [pii]
495 10.1053/j.jvca.2018.05.048
- 496 16. Baldea SM, Velcea AE, Rimbas RC, Andronic A, Matei L, Calin SI, Muraru D, Badano
497 LP, Vinereanu D. 3-D Echocardiography Is Feasible and More Reproducible than 2-D
498 Echocardiography for In-Training Echocardiographers in Follow-up of Patients with Heart
499 Failure with Reduced Ejection Fraction. *Ultrasound Med Biol*. 2021;47:499-510. doi: S0301-
500 5629(20)30485-3 [pii]
501 10.1016/j.ultrasmedbio.2020.10.022
- 502 17. Acar P, Laskari C, Rhodes J, Pandian N, Warner K, Marx G. Three-dimensional
503 echocardiographic analysis of valve anatomy as a determinant of mitral regurgitation after
504 surgery for atrioventricular septal defects. *Am J Cardiol*. 1999;83:745-749. doi:
505 S0002914998009825 [pii]

506 10.1016/s0002-9149(98)00982-5

507 18. Takahashi K, Mackie AS, Thompson R, Al-Naami G, Inage A, Rebeyka IM, Ross DB,
508 Khoo NS, Colen T, Smallhorn JF. Quantitative real-time three-dimensional echocardiography
509 provides new insight into the mechanisms of mitral valve regurgitation post-repair of
510 atrioventricular septal defect. *J Am Soc Echocardiogr.* 2012;25:1231-1244. doi: S0894-
511 7317(12)00678-5 [pii]

512 10.1016/j.echo.2012.08.011

513 19. Takahashi K, Guerra V, Roman KS, Nii M, Redington A, Smallhorn JF. Three-
514 dimensional echocardiography improves the understanding of the mechanisms and site of left
515 atrioventricular valve regurgitation in atrioventricular septal defect. *J Am Soc Echocardiogr.*
516 2006;19:1502-1510. doi: S0894-7317(06)00719-X [pii]

517 10.1016/j.echo.2006.07.011

518 20. Takahashi K, Inage A, Rebeyka IM, Ross DB, Thompson RB, Mackie AS, Smallhorn JF.
519 Real-time 3-dimensional echocardiography provides new insight into mechanisms of tricuspid
520 valve regurgitation in patients with hypoplastic left heart syndrome. *Circulation.* 2009;120:1091-
521 1098. doi: CIRCULATIONAHA.108.809566 [pii]

522 10.1161/CIRCULATIONAHA.108.809566

523 21. Wolbers M, Koller MT, Stel VS, Schaer B, Jager KJ, Leffondre K, Heinze G. Competing
524 risks analyses: objectives and approaches. *Eur Heart J.* 2014;35:2936-2941. doi: ehu131 [pii]

525 10.1093/eurheartj/ehu131

526 22. Staffa SJ, Zurakowski D. Competing risks analysis of time-to-event data for
527 cardiovascular surgeons. *J Thorac Cardiovasc Surg.* 2020;159:2459-2466 e2455. doi: S0022-
528 5223(19)32777-1 [pii]

529 10.1016/j.jtcvs.2019.10.153

- 530 23. Zhou B FJ, Laid G. . Stat Med. 2013 ;32 :3804-3811. Goodness-of-fit test for proportional
531 subdistribution hazards model. *Stat Med* 2013 ;32 :3804-3811
532 2013.
- 533 24. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more
534 correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*.
535 1988;44:837-845.
- 536 25. Staffa SJ, Zurakowski D. Statistical Development and Validation of Clinical Prediction
537 Models. *Anesthesiology*. 2021;135:396-405. doi: 116300 [pii]
538 10.1097/ALN.0000000000003871
- 539 26. Baghaei R, Tabib A, Jalili F, Totonchi Z, Mahdavi M, Ghadrdoost B. Early and Mid-
540 Term Outcome of Pediatric Congenital Mitral Valve Surgery. *Res Cardiovasc Med*.
541 2015;4:e28724. doi: 10.5812/cardiovascmed.28724v2
- 542 27. Stephens EH, Han J, Ginns J, Rosenbaum M, Chai P, Bacha E, Kalfa D. Outcomes and
543 Prognostic Factors for Adult Patients With Congenital Heart Disease Undergoing Primary or
544 Reoperative Systemic Atrioventricular Valve Surgery. *World J Pediatr Congenit Heart Surg*.
545 2017;8:346-353. doi: 10.1177/2150135117692974
- 546 28. Schleiger A, Miera O, Peters B, Schmitt KRL, Kramer P, Buracionok J, Murin P, Cho
547 MY, Photiadis J, Berger F, et al. Long-term results after surgical repair of atrioventricular septal
548 defect. *Interact Cardiovasc Thorac Surg*. 2019;28:789-796. doi: 5258054 [pii]
549 10.1093/icvts/ivy334
- 550 29. Ijsselhof R, Gauvreau K, Nido PD, Nathan M. Atrioventricular Valve Function Predicts
551 Reintervention in Complete Atrioventricular Septal Defect. *World J Pediatr Congenit Heart*
552 *Surg*. 2020;11:247-248. doi: 10.1177_2150135119893648 [pii]
553 10.1177/2150135119893648

- 554 30. Fong LS, Betts K, Ayer J, Andrews D, Nicholson IA, Winlaw DS, Orr Y. Predictors of
555 reoperation and mortality after complete atrioventricular septal defect repair. *Eur J Cardiothorac*
556 *Surg.* 2021;61:45-53. doi: 6277380 [pii]
557 10.1093/ejcts/ezab221
- 558 31. Prakash A, Lacro RV, Sleeper LA, Minich LL, Colan SD, McCrindle B, Covitz W,
559 Golding F, Hlavacek AM, Levine JC, et al. Challenges in echocardiographic assessment of mitral
560 regurgitation in children after repair of atrioventricular septal defect. *Pediatr Cardiol.*
561 2012;33:205-214. doi: 10.1007/s00246-011-0107-5
- 562 32. Yosefy C, Hung J, Chua S, Vaturi M, Ton-Nu TT, Handschumacher MD, Levine RA.
563 Direct measurement of vena contracta area by real-time 3-dimensional echocardiography for
564 assessing severity of mitral regurgitation. *Am J Cardiol.* 2009;104:978-983. doi: S0002-
565 9149(09)01123-0 [pii]
566 10.1016/j.amjcard.2009.05.043
- 567 33. Kaza E, Marx GR, Kaza AK, Colan SD, Loyola H, Perrin DP, Del Nido PJ. Changes in
568 left atrioventricular valve geometry after surgical repair of complete atrioventricular canal. *J*
569 *Thorac Cardiovasc Surg.* 2012;143:1117-1124. doi: S0022-5223(11)01132-9 [pii]
570 10.1016/j.jtcvs.2011.06.044
- 571 34. Sugeng L, Weinert L, Lang RM. Real-time 3-dimensional color Doppler flow of mitral
572 and tricuspid regurgitation: feasibility and initial quantitative comparison with 2-dimensional
573 methods. *J Am Soc Echocardiogr.* 2007;20:1050-1057. doi: S0894-7317(07)00120-4 [pii]
574 10.1016/j.echo.2007.01.032
- 575 35. Zeng X, Levine RA, Hua L, Morris EL, Kang Y, Flaherty M, Morgan NV, Hung J.
576 Diagnostic value of vena contracta area in the quantification of mitral regurgitation severity by

- 577 color Doppler 3D echocardiography. *Circ Cardiovasc Imaging*. 2011;4:506-513. doi:
578 CIRCIMAGING.110.961649 [pii]
579 10.1161/CIRCIMAGING.110.961649
- 580 36. Thavendiranathan P, Liu S, Datta S, Rajagopalan S, Ryan T, Igo SR, Jackson MS, Little
581 SH, De Michelis N, Vannan MA. Quantification of chronic functional mitral regurgitation by
582 automated 3-dimensional peak and integrated proximal isovelocity surface area and stroke
583 volume techniques using real-time 3-dimensional volume color Doppler echocardiography: in
584 vitro and clinical validation. *Circ Cardiovasc Imaging*. 2013;6:125-133. doi:
585 CIRCIMAGING.112.980383 [pii]
586 10.1161/CIRCIMAGING.112.980383
- 587 37. Marsan NA, Westenberg JJ, Ypenburg C, Delgado V, van Bommel RJ, Roes SD,
588 Nucifora G, van der Geest RJ, de Roos A, Reiber JC, et al. Quantification of functional mitral
589 regurgitation by real-time 3D echocardiography: comparison with 3D velocity-encoded cardiac
590 magnetic resonance. *JACC Cardiovasc Imaging*. 2009;2:1245-1252. doi: S1936-878X(09)00597-
591 X [pii]
592 10.1016/j.jcmg.2009.07.006
- 593 38. Zamorano J, de Agustin JA. Three-dimensional echocardiography for assessment of
594 mitral valve stenosis. *Curr Opin Cardiol*. 2009;24:415-419. doi:
595 10.1097/HCO.0b013e32832e165b
- 596 39. Medvedofsky D, Maffessanti F, Weinert L, Tehrani DM, Narang A, Addetia K, Mediratta
597 A, Besser SA, Maor E, Patel AR, et al. 2D and 3D Echocardiography-Derived Indices of Left
598 Ventricular Function and Shape: Relationship With Mortality. *JACC Cardiovasc Imaging*.
599 2018;11:1569-1579. doi: S1936-878X(17)30904-X [pii]
600 10.1016/j.jcmg.2017.08.023

- 601 40. Abudiab MM, Chao CJ, Liu S, Naqvi TZ. Quantitation of valve regurgitation severity by
602 three-dimensional vena contracta area is superior to flow convergence method of quantitation on
603 transesophageal echocardiography. *Echocardiography*. 2017;34:992-1001. doi:
604 10.1111/echo.13549
- 605 41. Simpson J, Lopez L, Acar P, Friedberg M, Khoo N, Ko H, Marek J, Marx G, McGhie J,
606 Meijboom F, et al. Three-dimensional echocardiography in congenital heart disease: an expert
607 consensus document from the European Association of Cardiovascular Imaging and the
608 American Society of Echocardiography. *Eur Heart J Cardiovasc Imaging*. 2016;17:1071-1097.
609 doi: jew172 [pii]
610 10.1093/ehjci/jew172
- 611 42. Maragiannis D, Little SH. 3D vena contracta area to quantify severity of mitral
612 regurgitation: a practical new tool? *Hellenic J Cardiol*. 2013;54:448-454.
- 613 43. Stellin G, Padalino MA, Vida VL, Boccuzzo G, Orru E, Biffanti R, Milanese O,
614 Mazzucco A. Surgical repair of congenital mitral valve malformations in infancy and childhood:
615 a single-center 36-year experience. *J Thorac Cardiovasc Surg*. 2010;140:1238-1244. doi: S0022-
616 5223(10)00484-8 [pii]
617 10.1016/j.jtcvs.2010.05.016
- 618
- 619

620 **Table 1.** Patients' baseline demographic and anatomical characteristics.
621

	Total Cohort (n=206)	Mitral Stenosis (n=105)	Mitral Regurgitation (n=75)	Mixed Disease (n=26)
Demographics				
Median age, months (IQR)	17.3 (4.6 - 56)	11.9 (5.3 - 43.7)	47.7 (5.3 – 72.9)	4.6 (1.4 – 21.2)
Median weight, kg (IQR)	9.1 (5 – 16.7)	8.4 (5.4 – 13.2)	13.7 (5.2 – 19.6)	5.1 (3.3 – 11.4)
Median follow up, months (IQR)	59.4 (18.3- 108.4)	63 (15.3 – 115.7)	55.2 (16.8 – 87.4)	76.8 (27.4 -108.4)
Anatomical characteristics				
Double orifice mitral valve	13 (6.3%)	8 (7.6%)	3 (4%)	2 (7.7%)
Annular dilatation	50 (24.3%)	4(3.8%)	39 (52%)	7 (26.9%)
Cleft leaflet	46 (22.3%)	0 (0%)	39 (52%)	7 (26.9%)
Elongated chordae	10 (4.9%)	0 (0%)	10 (13.3%)	0 (0%)
Shortened chordae	76 (36.9%)	47 (44.8%)	17 (22.7%)	12 (46.2%)
Absent chordae	14 (6.8%)	6 (5.7%)	4 (5.3%)	4 (15.4%)
Fused/closely spaced chordae	45 (21.8%)	37 (35.2%)	3 (4%)	5 (19.2%)
Secondary/abnormal chordae	84 (41.0%)	39 (37.1%)	26 (34.7%)	17 (65.4%)
Commissural fusion	30 (14.6%)	26 (24.8%)	0 (0%)	4 (15.4%)
Hammock valve (mitral arcade)	22 (10.7%)	12 (11.4%)	3 (4%)	7 (26.9%)
Stenosing mitral membrane	65 (31.6%)	62 (59.0%)	0 (0%)	3 (11.5%)
Endocardial fibroelastosis	62 (30.1%)	46 (43.8%)	8 (10.7%)	8 (30.8%)
Single dominant papillary muscle	27 (13.1%)	22 (21.0%)	4 (4%)	1 (3.8%)
Prolapse of the anterior leaflet	51 (24.8%)	5 (4.8%)	35 (46.7%)	11 (42.3%)
Thickened leaflets	110 (53.4%)	64 (61.0%)	30 (40.0%)	16 (61.5%)
Tethered leaflets	115 (55.8%)	58 (55.2%)	34 (45.3%)	23 (88.5%)
Tethered papillary muscles	94 (45.6%)	51 (48.6%)	23 (30.7%)	20(76.9%)
Closely spaced papillary muscles	34 (16.5%)	28 (26.7%)	0 (0%)	6(23.1%)

622
623
624
625

626 **Table 2. Univariate and Multivariable Competing Risks Analysis to identify predictors of mitral valve reoperation**

627

628

Variable	Univariate Analysis				Multivariable Analysis		
	N	HR	95% CI	P Value	Adjusted HR	95% CI	P Value
Baseline and preoperative characteristics							
Age < 1 year	200	3.26	(1.92, 5.52)	<0.001*	2.65	(1.13, 6.21)	0.025*
Weight (kg)	206	0.96	(0.91, 1.01)	0.076	0.99	(0.96, 1.04)	0.726
Biological gender	195						
Female		Reference	.	.	Reference	.	.
Male		1.18	(0.71, 1.95)	0.524	1.21	(0.70, 2.10)	0.494
Type of disease	206						
Mitral stenosis		1.71	(0.94, 3.14)	0.081	1.13	(0.56, 2.28)	0.726
Mitral regurgitation		Reference	.	.	Reference	.	.
Mixed		2.57	(1.16, 5.71)	0.020*	1.29	(0.50, 3.31)	0.600
Pulmonary hypertension	195	1.43	(0.87, 2.35)	0.159	0.87	(0.49, 1.56)	0.646
Thickened leaflets	206	1.22	(0.74, 2.00)	0.435	1.2	(0.64, 2.27)	0.570
Tethered leaflets	206	2.11	(1.23, 3.61)	0.007*	2	(1.05, 3.82)	0.035*
Endocardial fibroelastosis	205	1.16	(0.69, 1.95)	0.583	0.71	(0.40, 1.29)	0.263
Year of surgery	206	1.02	(0.96, 1.09)	0.472	1.03	(0.95, 1.12)	0.443
Postoperative imaging on 2D Echo							
2D Moderate or greater MR Postop	193	5.2	(3.07, 8.80)	<0.001*	4.26	(2.45, 7.40)	<0.001*
2D Moderate or greater MS Postop	201	2.03	(1.18, 3.46)	0.010*	1.67	(0.94, 2.97)	0.082

629

630 Competing risks modeling was computed using the Fine and Gray model, with mortality prior to reoperation as the competing event.

631 All the factors assessed at the univariate analysis (left) were included in the multivariable model. Multivariable model: N=183 patients,

632 57 of whom underwent MV-reoperation. MR: mitral regurgitation. MS: mitral stenosis. *Statistically significant.

633 **Table 3. Univariate and multivariable Cox regression analysis to predict mitral valve reoperation using 3D Echo variables**
 634

Mitral Stenosis and Mixed Disease Patients							
3D Echo Variable	N	Univariate Cox Analysis			Multivariable Cox Analysis		
		HR	95% CI	P Value	Adjusted HR	95% CI	P Value
Size of 3D-EOA preoperatively	50	2.79	(1.48, 5.25)	0.002*	1.30	(0.56, 3.00)	0.539
Size of 3D-EOA postoperatively	49	0.69	(0.35, 1.36)	0.283			
Change of the 3D-EOA	39	0.27	(0.12, 0.59)	0.001*	0.26	(0.07, 0.99)	0.049*
Size of 3D-VCRA postoperatively	25	1.42	(1.06, 1.90)	0.018*	0.75	(0.37, 1.53)	0.430
Change of 3D-VCRA	18	2.52	(1.16, 5.48)	0.020*	2.86	(1.09, 7.48)	0.032*
Mitral Regurgitation and Mixed Disease Patients							
3D Echo Variable	N	Univariate Cox Analysis			Multivariable Cox Analysis		
		HR	95% CI	P Value	Adjusted HR	95% CI	P Value
Size of 3D-EOA postoperatively	30	0.80	(0.39, 1.64)	0.536			
Change of 3D-EOA	30	0.96	(0.32, 2.82)	0.930			
Size of 3D-VCRA preoperatively	38	1.81	(1.19, 2.74)	0.005*	1.86	(0.84, 4.11)	0.127
Size of 3D-VCRA postoperatively	30	3.15	(1.86, 5.36)	<0.001*	1.05	(0.38, 2.91)	0.921
Change of 3D-VCRA	30	15.7	(4.65, 53.00)	<0.001*	11.77	(3.06, 45.3)	<0.001*
Size of the 3D annulus preoperatively	45	1.03	(0.91, 1.17)	0.649			
Size of the 3D annulus postoperatively	30	1.16	(0.98, 1.39)	0.086			
Change in 3D annulus size	29	4.24	(1.00, 18.3)	0.050*	1.93	(0.28, 13.4)	0.506

635
 636 Factors found to be statistically significant at univariate analysis were included in the multivariable model. Multivariable analysis
 637 for patients with mitral stenosis and mixed disease: N=18. Multivariable analysis for patients with mitral regurgitation and mixed
 638 disease: N=25. 3D-EOA: 3D effective orifice area; 3D-VCRA: 3D vena contracta regurgitant area. *Statistically significant.

639 Table 4. Predictive value of 2D and 3D echocardiography in assessing the risk of mitral valve
 640 reoperation based on receiver operating characteristics curve analysis and decision tree algorithms
 641

Mitral Stenosis and Mixed Disease Patients		
Metric	Change in 2D mean gradient	Change in 3D-EOA
AUC (95% confidence interval)	0.676 (0.508, 0.844)	0.847 (0.723, 0.970)
Best cut-off identified by the decision tree algorithm	< 30% increase	< 30% increase
Sensitivity	88% (23/26)	61% (11/18)
Specificity	37% (7/19)	95% (20/21)
PPV	66%	92%
NPV	70%	74%
Mitral Regurgitation and Mixed Disease Patients		
Metric	Change in 2D-VCRA	Change in 3D-VCRA
AUC (95% confidence interval)	0.720 (0.424, 0.903)	0.969 (0.916, 0.999)
Best cut-off identified by the decision tree algorithm	< 40% decrease	< 40% decrease
Sensitivity	47% (7/15)	93% (13/14)
Specificity	95% (21/22)	94% (15/16)
PPV	88%	93%
NPV	72%	94%

642
 643 AUC curves are plotted and compared in **Figure 3**. Decision tree algorithms are summarized in
 644 **Figure 4**. 3D-EOA: 3D effective orifice area. 3D-VCRA: 3D vena contracta regurgitant area.
 645 AUC, area under the curve. NPV: negative predictive value. PPV: positive predictive value.

646

647 **FIGURE LEGENDS**

648 **Figure 1**

649 *Measurement of 3D-EOA and 3D-VCRA*

650 Multiplanar reconstruction was used to locate the optimal cross-sectional plane to determine the
651 annulus area, 3D-EOA (**A**) and 3D-VCRA (**B**). The 3D-EOA was defined as the smallest orifice
652 of the MV inflow. The 3D-VCRA corresponded to the cross-sectional area of the color Doppler
653 jet at valve coaptation. **A.** For 3D-EOA measurement, the frame during diastolic opening with the
654 largest opening was chosen and the MV was aligned in two long-axis orthogonal planes. A cross-
655 sectional plane (blue) was set at the desired position to allow for 3D-EOA circumference
656 planimetry. **B.** For 3D-VCRA measurement, the longitudinal planes were adjusted to best
657 visualize the regurgitant jet, allowing for placement of the cross-sectional plane at the largest
658 circumference; 3D-VCRA was then measured before jet dispersion in orthogonal imaging planes.
659 EOA: effective orifice area. MV: mitral valve. VCRA: vena contracta regurgitant area.

660

661 **Figure 2**

662 *Competing risk analysis cumulative incidence curves for MV-reoperation according to evidence*
663 *of moderate or greater postoperative MR by 2DE*

664 **A.** The risk of MV reoperation was significantly higher in patients with moderate or greater
665 postoperative MR (adjusted HR=4.26; 95% CI: 2.45-7.4). **B,C.** This association persisted for
666 each baseline anatomic disease group (MS+MD patients: adjusted HR=3.21; 95% CI: 1.73-6.0;
667 MR+MD patients: adjusted HR=7.38; 95% CI: 3.46-15.7). Multivariable models were adjusted
668 for demographic, anatomic, and clinical characteristics shown in **Table 2**. 2DE: 2D
669 echocardiography, EOA: effective orifice area, HR: hazard ratio, CI: confidence interval, MD:

670 mixed disease, MR: mitral regurgitation, MS: mitral stenosis, MV: mitral valve, VCRA: vena
671 contracta regurgitant area.

672

673 **Figure 3**

674 *Comparison of 2DE versus 3DE predictive accuracy in predicting MV reoperation by AUC*

675 **A.** When considering stenotic valves, AUC curve comparison revealed that early changes in 3D-

676 EOA was a stronger predictor of MV reoperation than early changes in 2DE mean gradients

677 (AUC 0.847 [95% CI: 0.723, 0.970] vs 0.676 [95% CI: 0.508, 0.844], respectively; DeLong test

678 $P=0.006$). **B.** For regurgitant valves, AUC analysis revealed that early changes in 3D-VCRA was

679 a significantly stronger predictor of MV reoperation than 2DE early changes in 2D-VCRA

680 (AUC=0.969 [95% CI: 0.916, 0.999] vs 0.720 [95% CI: 0.424, 0.903], DeLong test $P=0.012$).

681 2DE/3DE: 2D/3D echocardiography, AUC: area under the curve, EOA: effective orifice area, CI:

682 confidence interval, MV: mitral valve, VCRA: vena contracta regurgitant area.

683

684 **Figure 4**

685 *Decision-tree predictive algorithms for risk stratification*

686 For stenotic valves, an increase in 3D-EOA by <30% leads to 92% risk of MV reoperation

687 (accuracy 80%; HR=8.5; 95% CI: 2.9-25.1). For regurgitant valves, a decrease in 3D-VCRA

688 <40% is associated with 93% risk of reoperation (accuracy 93%; HR=22.5; 95% CI: 2.9-175).


689 Sensitivity, specificity, PPV and NPV are reported in **Table 4**. Bootstrap validation demonstrated

690 excellent internal validity and model performance (**Supplemental Results**). AUC: area under the

691 curve, EOA: effective orifice area, CI: confidence interval, hazard ratio: HR, MV: mitral valve,


692 NPV: negative predictive value, PPV: positive predictive value, VCRA: vena contracta

693 regurgitant area.




Reoperation on the Mitral Valve


A




B




C




A



B



Mitral Stenosis



Mitral Regurgitation

